A Case of Tumor Necrosis Factor-α Inhibitors-induced Pustular Psoriasis
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Anti-tumor necrosis factor (TNF)-α agents promise better disease control for the treatment of ankylosing spondylitis resistant to classical disease-modifying treatments. Etanercept,a recombinant human TNF receptor fusion protein, is used to treat a variety of TNF-α-mediated diseases by inhibiting the biological activity of TNF-α. We experienced a case of pustular psoriasis in a 32-year-old man during anti-TNF-αtherapy with etanercept. He had a history of ankylosing spondylitis for 2 years. Two years after treatment of etanercept,erythematous pustules developed on his palms and soles. He had no previous history of pustular psoriasis. The skin lesion improved as the etanercept therapy was stopped,but pustular skin eruption recurred as adalimumab, a different TNF-α inhibitor, was administered to manage his ankylosing spondylitis. Several TNF-α inhibitors have different molecular structures, but these inhibitors might have a similar potency to induce pustular psoriasis from this case. (Ann Dermatol 22(2) 212∼215, 2010)
Abstract
Anti-tumor necrosis factor (TNF)-α agents promise better disease control for the treatment of ankylosing spondylitis resistant to classical disease-modifying treatments. Etanercept,a recombinant human TNF receptor fusion protein, is used to treat a variety of TNF-α-mediated diseases by inhibiting the biological activity of TNF-α. We experienced a case of pustular psoriasis in a 32-year-old man during anti-TNF-αtherapy with etanercept. He had a history of ankylosing spondylitis for 2 years. Two years after treatment of etanercept,erythematous pustules developed on his palms and soles. He had no previous history of pustular psoriasis. The skin lesion improved as the etanercept therapy was stopped,but pustular skin eruption recurred as adalimumab, a different TNF-α inhibitor, was administered to manage his ankylosing spondylitis. Several TNF-α inhibitors have different molecular structures, but these inhibitors might have a similar potency to induce pustular psoriasis from this case. (Ann Dermatol 22(2) 212∼215, 2010)
참고문헌 (16)
- de Gannes GC, "Psoriasis and pustular dermatitis triggered by TNF-alpha in patients with rheumatologic conditions", Arch Dermatol, 143, pp.223~231 (2007)
- Dika E, "Drug-induced psoriasis:an evidence-based overview and the introduction of psoriatic drug eruption probability score", Cutan Ocul Toxicol, 25, pp.1~11 (2006)
- 최윤진, "Tumor Necrosis Factor-alpha (TNF-α) 길항제를 사용한 후 악화된 건선모양 발진 1예", 대한피부과학회지, 46(5), pp.721~723 (2008), 대한피부과학회
- Tracey D, "Tumor necrosis factor antagonist mechanisms of action:a comprehensive review", Pharmacol Ther, 117, pp.244~279 (2008)
- Romero-Mate A, "Efficacy and safety of etanercept in psoriasis", psoriatic arthritis:an updated review, 2007, pp.8, 143~155
- Collamer AN, "Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy:a literature review and potential mechanisms of action", Arthritis Rheum, 59, pp.996~1001 (2008)
- Nestle FO, "Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production", J Exp Med, 202, pp.135~143 (2005)
- Olsen NJ, "New drugs for rheumatoid arthritis", N Engl J Med, 350, pp.2167~2179 (2004)
- Braun J, "Treatment of active ankylosing spondylitis with infliximab:a randomised controlled multicentre trial", Lancet, 359, pp.1187~1193 (2002)
- Goffe B, "Etanercept: an overview", J Am Acad Dermatol, 49, pp.S105~S111 (2003)
- Solau-Gervais E, "Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody", Rheumatology(Oxford), 45, pp.1121~1124 (2006)
- Haibel H, "No efficacy of subcutaneous methotrexate in active ankylosing spondylitis:a 16-week open-label trial", Ann Rheum Dis, 66, pp.419~421 (2007)
- Lee JG, "Clinical improvement of ankylosing spondylitis on switching tumor necrosis factor inhibitors: a case report", Korean J Med, 75, pp.S930~S934 (2008)
- Laas K, "Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis", Clin Rheumatol, 27, pp.927~932 (2008)
- Bombardieri S, "Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice", Rheumatology(Oxford), 46, pp.1191~1199 (2007)
- Conti F, "Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis:an observational study over a 5-year period", Ann Rheum Dis, 66, pp.1393~1397 (2007)